RxDoctor Payments Data

Murali Bathina, MD

Cardiovascular Disease · Caldwell, IDNPI 1265486625

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,745 of the $5,149 with a category attached, or 72.7%. Boston Scientific accounts for 77.4% of it on its own, with 8 other manufacturers making up the rest.

$5,149in general payments, 2019–2025

Across 182 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Abbott$933
  • Heartflow, Inc.$90
  • Bracco Diagnostics Inc.$32
  • AstraZeneca$28
  • Abiomed$26
  • plus $55 from 3 others

What the payments were for

  • Travel & lodging$1,38327%
  • Food & beverage$3,74573%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,149 in reported general payments places this provider in the 70th percentile of 59 cardiovascular disease providers in Idaho.

See all cardiovascular disease providers in Idaho

Medicare billing

Part B allowed, 2024
$73,069
Medicare patients
1,337
Services billed
1,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$166,373
FarxigaDapagliflozin Propanediol21$22,257
XareltoRivaroxaban13$16,326
Repatha SureclickEvolocumab12$7,730
Metoprolol Succinate173$2,139
Amiodarone Hcl24$1,915
Diltiazem 24hr Er (Cd)Diltiazem Hcl37$984
Potassium Chloride24$900
Eplerenone11$807
Atorvastatin Calcium76$702
Digoxin33$652
Warfarin Sodium57$650
Carvedilol85$561
Amlodipine Besylate56$496
Metoprolol Tartrate45$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$28$22,25721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 59 cardiovascular disease providers in Idaho.

Other cardiovascular disease in Caldwell

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →